1. Ting, J. P. and D. F. Ranney. 1980. Selective suppression of the murine autologous mixed lymphocyte reaction by physiological concentrations of hydrocortisone: effects on cell-surface Ia antigens. Cell Immunol. 53:138.

2. Ting, J. P., B. L. Shigekawa, D. S. Linthicum, L. P. Weiner, and J. A. Frelinger. 1981. Expression and synthesis of murine immune response-associated (Ia) antigens by brain cells. Proc. Natl. Acad. Sci. U. S. A. 78:3170.

3. Ting, J. P., D. F. Nixon, L. P. Weiner, and J. A. Frelinger. 1983. Brain Ia antigens have a bone marrow origin. Immunogenetics 17:295.

4. Howell, D. N., D. D. Kostyu, J. P. Ting, and P. Cresswell. 1984. Expression of class I histocompatibility antigens on human T-B lymphoblast hybrids. Somat. Cell Mol. Genet. 10:217.

5. Tajima, S., J. P. Ting, S. R. Pinnell, and R. E. Kaufman. 1984. Isolation and characterization of a human pro alpha 2(I) collagen gene segment. J. Invest. Dermatol. 82:265.

6. Carrington, M. N., R. D. Salter, P. Cresswell, and J. P. Ting. 1985. Evidence for methylation as a regulatory mechanism in HLA-DR alpha gene expression. Immunogenetics. 22:219.

7. Takiguchi, M., J. P. Ting, S. C. Buessow, C. Boyer, Y. Gillespie, and J. A. Frelinger. 1985. Response of glioma cells to interferon-gamma: increase in class II RNA, protein and mixed lymphocyte reaction-stimul ating ability. Eur J Immunol. 15:809.

8. Ting, J. P., M. N. Carrington, R. D. Salter, R. DeMars, and P. Cresswell. 1985. Evidence for chromatin structure as a regulatory determinant in HLA-DR alpha gene expression. Immunogenetics. 22:571.

9. Basta, P. V., P. A. Sherman, and J. P. Ting. 1987. Identification of an interferon-gamma response region 5' of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human gliobla stoma multiforme lines. J Immunol. 138:1275.

10. Carrington, M. N., M. Chedid, J. P. Ting, and F. E. Ward. 1987. Differential expression of the HLA-DR genes in various melanoma cell lines treated with interferon-gamma: methylation of the HLA-DR alpha gene in these lines is not correlated with its expression. Hum Immunol. 18:151.

11. Evans, J. L., W. J. Boyle, and J. P. Ting. 1987. Molecular basis of elevated c-myb expression in the abnormal L3T4-, Lyt-2- T lymphocytes of autoimmune mice. J Immunol. 139:3497.

12. Sherman, P. A., P. V. Basta, and J. P. Ting. 1987. Upstream DNA sequences required for tissue- specific expression of the HLA-DR alpha gene. Proc Natl Acad Sci U S A. 84:4254.

13. Ting, J. P., M. Takiguchi, M. Macchi, and J. A. Frelinger. 1987. The expression and detection of MHC class I antigens on murine neuroblastoma and ependymoblastoma lines. J Neuroimmunol. 14:87.

14. Yokota, S., D. Yuan, T. Katagiri, R. A. Eisenberg, P. L. Cohen, and J. P. Ting. 1987. The expression and regulation of c-myb transcription in B6/lpr Lyt-2-, L3T4-T lymphocytes. J Immunol. 139:2810.

15. Basta, P. V., P. A. Sherman, and J. P. Ting. 1988. Detailed delineation of an interferon-gamma- responsive element important in human HLA-DRA gene expression in a glioblastoma multiform line. Proc Natl Acad Sci U S A. 85:8618.

16. Katagiri, K., T. Katagiri, S. Yokota, R. A. Eisenberg, P. L. Cohen, and J. P. Ting. 1988. Two different molecular pathways account for low IL-2 receptor and c-myc mRNA expression by lpr Lyt-2- L3T4- T cells. J Immunol. 141:2145.

17. Basta, P. V., T. L. Moore, S. Yokota, and J. P. Ting. 1989. A beta-adrenergic agonist modulates DR alpha gene transcription via enhanced cAMP levels in a glioblastoma multiforme line. J Immunol. 142:2895.

18. Katagiri, T., J. P. Ting, R. Dy, C. Prokop, P. Cohen, and H. S. Earp. 1989. Tyrosine phosphorylation of a c-Src-like protein is increased in membranes of CD4- CD8- T lymphocytes from lpr/lpr mice. Mol Cell Biol. 9:4914.

19. Sasaki, A., S. W. Levison, and J. P. Ting. 1989. Comparison and quantitation of Ia antigen expression on cultured macroglia and ameboid microglia from Lewis rat cerebral cortex: analyses and implications. J Neuroimmunol. 25:63.

20. Sherman, P. A., P. V. Basta, A. Heguy, M. K. Wloch, R. G. Roeder, and J. P. Ting. 1989. The octamer motif is a B-lymphocyte-specific regulatory element of the HLA-DR alpha gene promoter. Proc Natl Acad Sci U S A. 86:6739.

21. Sherman, P. A., P. V. Basta, T. L. Moore, A. M. Brown, and J. P. Ting. 1989. Class II box consensus sequences in the HLA-DR alpha gene: transcriptional function and interaction with nuclear proteins. Mol C ell Biol. 9:50.

22. Cogswell, J. P., P. V. Basta, and J. P. Ting. 1990. X-box-binding proteins positively and negatively regulate transcription of the HLA-DRA gene through interaction with discrete upstream W and V elements. Proc Natl Acad Sci U S A. 87:7703.

23. Evans, J. L., T. L. Moore, W. M. Kuehl, T. Bender, and J. P. Ting. 1990. Functional analysis of c-Myb protein in T-lymphocytic cell lines shows that it trans-activates the c-myc promoter. Mol Cell Biol. 10 :5747.

24. Liou, H. C., M. R. Boothby, P. W. Finn, R. Davidon, N. Nabavi, N. J. Zeleznik Le, J. P. Ting, and L. H. Glimcher. 1990. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science. 247:1581.

25. Sasaki, A., S. W. Levison, and J. P. Ting. 1990. Differential suppression of interferon- gamma-induced Ia antigen expression on cultured rat astroglia and microglia by second messengers. J Neuroimmunol. 29 :213.

26. Brown, A. M., C. L. Barr, and J. P. Ting. 1991. Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-gamma- induced expression of human class II-associated invariant chain gene. J Immunol. 146:3183.

27. Cogswell, J. P., N. Zeleznik Le, and J. P. Ting. 1991. Transcriptional regulation of the HLA-DRA gene. Crit Rev Immunol. 11:87.

28. Cogswell, J. P., J. Austin, and J. P. Ting. 1991. The W element is a positive regulator of HLA-DRA transcription in various DR+ cell types [published erratum appears in J Immunol 1991 May 1;146(9):3260-1]. J Immunol. 146:1361.

29. Moses, H., A. Sasaki, and J. P. Ting. 1991. Identification of an interferon-gamma- responsive element of a class II major histocompatibility gene in rat type 1 astrocytes. J Neuroimmunol. 31:273.

30. Vilen, B. J., J. P. Cogswell, and J. P. Ting. 1991. Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function. Mol Cell Biol. 11: 2406.

31. Zeleznik Le, N. J., J. C. Azizkhan, and J. P. Ting. 1991. Affinity-purified CCAAT-box-binding protein (YEBP) functionally regulates expression of a human class II major histocompatibility complex gene and the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 88:1873.

32. Gaur, L. K., E. R. Heise, and J. P. Ting. 1992. Conservation of the promoter region of DRA-like genes from nonhuman primates. Immunogenetics. 35:136.

33. Matsushima, G. K., Y. Itoh Lindstrom, and J. P. Ting. 1992. Activation of the HLA-DRA gene in primary human T lymphocytes: novel usage of TATA and the X and Y promoter elements [published erratum appears in Mol Cell Biol 1993 Aug;13(8):5132]. Mol Cell Biol. 12:5610.

34. Moses, H., R. B. Panek, E. N. Benveniste, and J. P. Ting. 1992. Usage of primary cells to delineate IFN-gamma-responsive DNA elements in the HLA-DRA promoter and to identify a novel IFN-gamma-enhanced nuclear factor. J Immunol. 148:3643.

35. Panek, R. B., H. Moses, J. P. Ting, and E. N. Benveniste. 1992. Tumor necrosis factor alpha response elements in the HLA-DRA promoter: identification of a tumor necrosis factor alpha-induced DNA-protein complex in astrocytes. Proc Natl Acad Sci U S A. 89:11518.

36. Vilen, B. J., J. F. Penta, and J. P. Ting. 1992. Structural constraints within a trimeric transcriptional regulatory region. Constitutive and interferon- gamma-inducible expression of the HLA-DRA gene. J Biol Chem. 267:23728.

37. Wright, K. L. and J. P. Ting. 1992. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up- regulation of X box binding by interferon gamma. Proc Natl Acad Sci U S A. 89:7601.

38. Zeleznik Le, N. J., Y. Itoh Lindstrom, J. B. Clarke, T. L. Moore, and J. P. Ting. 1992. The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene, DRA. J Biol Chem. 267:7677.

39. Brown, A. M., K. L. Wright, and J. P. Ting. 1993. Human major histocompatibility complex class II-associated invariant chain gene promoter. Functional analysis and in vivo protein/DNA interactions of constit utive and IFN-gamma-induced expression. J Biol Chem. 268:26328.

40. Cogswell, J. P., P. C. Cogswell, W. M. Kuehl, A. M. Cuddihy, T. M. Bender, U. Engelke, K. B. Marcu, and J. P. Ting. 1993. Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol Cell Biol. 13:2858.

41. Ting, J. P. 1993. Current concepts in DRA gene regulation. Immunol Res. 12:65.

42. Ting, J. P. and A. S. Baldwin . 1993. Regulation of MHC gene expression. Curr Opin Immunol. 5:8.

43. Brown, A. M., M. W. Linhoff, B. Stein, K. L. Wright, A. S. J. Baldwin, P. V. Basta, and J. P. Ting . 1994. Function of NF-kappa B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits. Mol Cell Biol. 14:2926.

44. Chen, X., K. L. Wright, E. A. Berkowitz, J. C. Azizkhan, J. P. Ting, and D. C. Lee. 1994. Protein interactions at Sp1-like sites in the TGF alpha promoter as visualized by in vivo genomic footprinting. Oncogene 9:3179.

45. Chin, K.-C., C. Mao, C. Skinnner, J. L. Riley, K. L. Wright, C. S. Moreno, G. R. Stark, J. M. Boss, and J. P. Ting. 1994. Molecular Analysis of G1B and G3A IFN-gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity 1:687.

46. Matsushima, G. K., M. Taniike, L. H. Glimcher, M. J. Grusby, J. A. Frelinger, K. Suzuki, and J. P. Ting. 1994. Absence of MHC class II molecules reduce CNS demyelination, microglial/macrophage infiltration and twitching in murine globoid cell leukokystrophy. Cell 78:645.

47. Ting, J. P., A. Painter, N. J. Zeleznik Le, G. MacDonald, T. M. Moore, A. Brown, and B. D. Schwartz. 1994. YB-1 DNA-binding protein represses interferon gamma activation of class II major histocompatibility complex genes. J Exp Med. 179:1605.

48. Wright, K. L., T. M. Moore, and J. P. Ting. 1994. CCAAT box binding proteins facilitate in vivo recruitment of upstream DNA binding transcription factors. EMBO J. 13:4042.

49. Itoh-Lindstrom, Y., B. M. Peterlin, and J. P. Ting. 1995. Affinity enrichment and functional characterization of TRAX1, a novel transcription activator and X1-sequence- binding protein of HLA-DRA. Mol. Cell Biol. 15:282.

50. MacDonald, G. H., Y. Itoh-Lindstrom, and J. P. Ting. 1995. The transcriptional regulatory protein, YB-1, promotes single-stranded regions in the DRA promoter. J. Biol. Chem. 270:3527.

51. Wright, K. L., L. C. White, A. Kelly, S. Beck, J. Trowsdale, and J. P. Ting. 1995. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J. Exp. Med. 181:1459.

52. Kenneth L. Wright, Terry L. Moore, Barbara J. Vilen, Adrienne M. Brown, and Jenny P.-Y. Ting. 1995. Major Histocompatibility Complex Class II-associated Invariant Chain Gene Expression Is Up-regulated by Cooperative Interactions of Sp1 and NF-Y. J. Biol. Chem. 270 (36): 20978-20986.

53. Lee, L.-F., C. C. Schuerer-Maly, A. K. Lofquist, C. van Haften-Day, J. P. Ting, C. M. White, B. K. Martin, and J. S. Haskill. 1996. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 56:1303.

54. White, L. C., K. L. Wright, N. J. Felix, H. Ruffner, L. F. Reis, R. Pine, and J. P. Ting. 1996. Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1-/- mice. Immunity. 5:365.

55. Hellendall, R. P. and J. P. Ting. 1997. Differential regulation of cytokine-induced major histocompatibility complex class II expression and nitric oxide release in rat microglia and astrocytes by effectors of tyrosine kinase, protein kinase C, and cAMP. J. Neuroimmunol. 74:19.

56. Chin, K. C., G. G. Li, and J. P. Ting. 1997. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc. Natl. Acad. Sci. U. S. A. 94:2501.

57. Martin, B. K., K. C. Chin, J. C. Olsen, C. A. Skinner, A. Dey, K. Ozato, and J. P. Ting. 1997. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity. 6:591.

57. Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, Ting JP, Yates J, Cogswell JP. 1997. . Cyclin-dependent kinase activation and S-phase induction of the cyclin B1 gene are linked through the CCAAT elements. Cell Growth Diff. 8:811.

58. Linhoff MW, Wright KL, Ting JP 1997. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol. Cell. Biol. 17:4589.

59. Armstrong TD, Clements VK, Martin BK, Ting JPY, Ostrand-Rosenberg S 1997. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Nat. Acad. Sci. USA. 94:6886.

60. Sundseth, R., MacDonald, G., Ting, J., King, A.C. 1997. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug resistance gene promoter. Molecular Pharmacology. 51:963-971.

61. Lee LF, Haskill JS, Mukaida N, Matsushima K, Ting JP. 1997. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol Cell Biol 1997 Sep;17(9):5097-105.

62. Zimmermann AG, Wright KL, Ting JP, Mitchell BS. 1997. Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. J Biol Chem 1997 Sep 5;272(36):22913-23.

63. Chin KC, Li G, Ting JP. 1997. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants. J Immunol 1997 Sep 15;159(6):2789-94.

64. Ting JP, Wright KL, Chin KC, Brickey WJ, Li G. 1997. The DMB promoter: delineation, in vivo footprint, trans-activation, and trans-dominant suppression. J Immunol 1997 Dec 1;159(11):5457-62.

65. Montani V, Taniguchi SI, Shong M, Suzuki K, Ohmori M, Giuliani C, Napolitano G, Saji M, Fiorentino B, Reimold AM, Ting JP, Kohn LD, Singer DS. 1997. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by the class II transactivator and the thyroid Y box protein. Endocrinology 1998 Jan;139(1):280-9.

66. Piskurich JF, Wang Y, Linhoff MW, White LC, Ting JP. 1998. Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J Immunol 1998 Jan 1;160(1):233-40.

67. White CM, Martin BK, Lee LF, Haskill JS, Ting JP. 1998. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 1998 Apr;46(2):104-12.

68. Godbold GD, Ahn K, Yeyeodu S, Lee LF, Ting JP, Erickson AH. 1998. Biosynthesis and intracellular targeting of the lysosomal aspartic proteinase cathepsin D. Adv Exp Med Biol 1998;436:153-62.

69. Wright KL, Chin KC, Linhoff M, Skinner C, Brown JA, Boss JM, Stark GR, Ting JP. 1998. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo. Proc Natl Acad Sci U S A 1998 May 26;95(11):6267-72

70. Lee LF, Li G, Templeton DJ, Ting JP. 1998. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 1998 Oct 23;273(43):28253-60.

71. Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsushima GK. 1998. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 1998 Dec 1;92(1-2):38-49.

72. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000 Oct 18.

73. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol. 2000 Sep;20(17):6185-94.

74. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol. 2000 Aug;20(16):6051-61.

75. Taxman DJ, Cressman DE, Ting JP.  Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer. J Immunol. 2000 Aug 1;165(3):1410-6.

76. Felix NJ, Brickey WJ, Griffiths R, Zhang J, Van Kaer L, Coffman T, Ting JP.  H2-DMalpha(-/-) mice show the importance of major histocompatibility complex-bound peptide in cardiac allograft rejection.  J Exp Med. 2000 Jul 3;192(1):31-40.

77. Collins TS, Lee LF, Ting JP. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother. 2000 May;49(2):78-84.

78. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP.  IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol. 2000 Mar 1;164(5):2769-75.

79. Ting JP, Zhu XS.  Class II MHC genes: a model gene regulatory system with great biologic consequences.
Microbes Infect. 1999 Sep;1(11):855-61. Review.

80. Brickey WJ, Wright KL, Zhu XS, Ting JP.  Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.
J Immunol. 1999 Dec 15;163(12):6622-30.

81. Ghosh N, Piskurich JF, Wright G, Hassani K, Ting JP, Wright KL.   A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J Biol Chem. 1999 Nov 5;274(45):32342-50.

82. Nikcevich KM, Piskurich JF, Hellendall RP, Wang Y, Ting JP.  Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J Neuroimmunol.1999 Oct 29;99(2):195-204.

83. Harton JA, Cressman DE, Chin KC, Der CJ, Ting JP.  GTP binding by class II transactivator: role in nuclear import. Science 1999 Aug 27;285(5432):1402-5.

84. Itoh-Lindstrom Y, Piskurich JF, Felix NJ, Wang Y, Brickey WJ, Platt JL, Koller BH, Ting JP.  Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. J Immunol 1999 Sep 1;163(5):2425-31.

85. Martin BK, Frelinger JG, Ting JP.  Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol 1999 Jun 1;162(11):6663-70.

86. Cressman DE, Chin KC, Taxman DJ, Ting JP.  A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 1999 Feb;10(2):163-71.

87. Piskurich JF, Linhoff MW, Wang Y, Ting JP.  Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta.  Mol Cell Biol 1999 Jan;19(1):431-40.